The estimated incidence and proportion positive of RSV disease in EMC is substantially lower than HIC, and narrow case definitions requiring fever, less sensitive testing such as direct fluorescent antibody testing, reduced healthcare access, and incomplete surveillance may be contributing to these lower estimates.
Sebastien Kenmoe, B. Wahi-Singh, P. Wahi-Singh et al.· Open Forum Infectious Diseas...· 0 citations
Individuals living with heart failure (HF) are predisposed to severe cardio-respiratory disease (CRD) complications following respiratory syncytial virus (RSV) infection. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine reduced the risk of hospitalization for RSV-related respiratory tract disease (RTD),...
K. Skaarup, M. Lassen, M. Yafasov et al.· European Heart Journal· 0 citations
Myocarditis and pericarditis are inflammatory cardiac syndromes that have been monitored as outcomes of special interest in adult vaccination programs. Previous randomized and observational studies of RSVpreF vaccination have not identified an association with these events; however, given their low incidence, pri...
M. Yafasov, M. Pareek, M. Lassen et al.· European Heart Journal· 0 citations
INTRODUCTION
Respiratory syncytial virus (RSV) and influenza cause substantial acute respiratory illness (ARI) and may be difficult to distinguish clinically. We compared characteristics of adults hospitalized with ARI, diagnosed with RSV versus influenza, using standardized systematic testing.
METHODS
The North Amer...
N. Aliabadi, Hammad Ali, Qing Liu et al.· Infectious Disease and Thera...· 0 citations
A prespecified analysis of the complete two-season DAN-RSV trial cohort will examine the vaccine effectiveness (VE) of RSVpreF versus no vaccine on respiratory and CV events among participants with or without pre-existing ASCVD.
M. Pareek, M. Lassen, M. Yafasov et al.· European Heart Journal· 0 citations
Respiratory syncytial virus (RSV) protein subunit vaccines reduce the risk of severe outcomes such as hospitalization and emergency department (ED) visits for at least two RSV seasons following vaccination. No data have been published on real-world RSV vaccine effectiveness (VE) beyond the second season after vaccinati...
Sara Y. Tartof, E. Zasowski, N. Aliabadi et al.· Infectious Disease and Thera...· 0 citations
BACKGROUND
Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...
M. Lassen, S. Christensen, M. Yafasov et al.· NEJM Evidence· 1 citation
Background The burden and seasonal patterns of respiratory syncytial virus (RSV), influenza, and COVID-19 remain poorly characterised in Brazil and other Latin American countries. Understanding their epidemiological patterns is essential to inform public health interventions and preventive strategies. We aimed to asses...
G. S. Julian, J. Spinardi, Ana Paula Flora et al.· Journal of Global Health· 0 citations
Precision of VE against RSV-related ARI ED/hospital admissions improved substantially with inclusion of salvage testing compared to SOC testing alone, suggesting that frequent standard-of-care RSV testing contributes to underestimated disease burden.
B. Ackerson, Brandon Chia, N. Aliabadi et al.· Open Forum Infectious Diseas...· 0 citations
In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.
A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al.· The Lancet Healthy Longevity· 0 citations
BACKGROUND
Although evidence suggests some direct protection against Streptococcus pneumoniae serotype 3 (Spn3) from the 13-valent pneumococcal conjugate vaccine (PCV13), Spn3 remains a common cause of pneumococcal disease. We aimed to assess whether serotype-specific humoral immune responses to capsule polysaccharide...
P. Gonzalez-Dias, A. Gonçalves, J. Reiné et al.· The Lancet Microbe· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.